Effect of FOXO1 and PXR on drug resistance of imatinib in chronic myeloid leukemia

Effect and mechanism of FOXO1 co-activated PXR on drug resistance of imatinib in chronic myeloid leukemia

Status

Recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR1800019896

Enrollment

Unknown

Registered

2018-12-07

Start date

2018-12-31

Completion date

Unknown

Last updated

2018-12-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

chronic myeloid leukemia

Interventions

Imatinib effective group:Determination of BCR-ABL fusion gene IS value0.1%

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) diagnosed as Ph+ chronic myeloid leukemia CP phase; 2) aged =18 years; 3) no malignant tumor other than CML; 4) dose of imatinib (400mg/day), taking time =3 Months and daily time fixed, medications reached steady state; 5) good compliance for medication, complete relevant examination and the follow-up.

Exclusion criteria

Exclusion criteria: 1) The patient is detected as a BCR-ABL kinase mutation; 2) The patient has a malignant tumor other than CML.

Design outcomes

Primary

Measure	Time frame
BCR-ABL fusion gene;Imatinib plasma concentration;PXR/FOXO1 gene polymorphism;PXR/FOXO1 mRNA expression;	—

Countries

China

Contacts

Public ContactPing Xu

the Second Xiangya Hospital, Central South University

xuping1109@163.com+86 18867352068

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026